MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR MULTIPLE MYELOMA
Rs 15,600 Rs 12,000
23 % OFF
DETECTION OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PREDICTS OUTCOME, HELPS IDENTIFY IMPENDING RELAPSE AND ENABLES EARLY INTERVENTION, BETTER POST TRANSPLANT SURVEILLANCE AND BETTER CLINICAL MANAGEMENT OF PATIENTS. IT CAN DETECT SUB-MICROSCOPIC LEVELS OF LEUKEMIA. MRD NEGATIVITY IS ASSOCIATED WITH IMPROVED PFS AND OS. PROGNOSTIC IMPACT OF MRD NEGATIVITY IS INDEPENDENT OF INDUCTION THERAPY.
Why book with us?
-
Free and On Schedule Sample Collection
-
24/7 Service
-
Affordable
-
Quick and Accurate Reports
3 ML (1 ML MIN.) BONE MARROW (FIRST PULL ASPIRATE) IN 1 GREEN TOP (SODIUM HEPARIN) TUBE. MIX THOROUGHLY & SHIP IMMEDIATELY AT 18-22 C OR AT 2-8 C. DO NOT FREEZE. FOLLOWING INFORMATION IS MANDATORY: SAMPLE TIME POINT (CHEMOTHERAPY TIME POINTS); PREVIOUS DIAGNOSTIC IMMUNOPHENOTYPE REPORT; CLINICAL HISTORY SPECIALLY MENTION IF PATIENT IS ON ANTI-CD38 THERAPY; ORIGINAL TRF; DATE AND TIME WHEN SAMPLE WAS DRAWN; 1 OR 2 UNSTAINED BMA SMEARS TO BE MADE AT SOURCE.
FLOW CYTOMETRY
REPORT ON 4TH DAY EVENING 7PM
FOLLOWING INFORMATION IS MANDATORY: SAMPLE TIME POINT (CHEMOTHERAPY TIME POINTS); PREVIOUS DIAGNOSTIC IMMUNOPHENOTYPE REPORT; CLINICAL HISTORY SPECIALLY MENTION IF PATIENT IS ON ANTI-CD38 THERAPY; ORIGINAL TRF; DATE AND TIME WHEN SAMPLE WAS DRAWN; 1 OR 2 UNSTAINED BMA SMEARS TO BE MADE AT SOURCE.
